Genetic polymorphisms of long non-coding RNA GAS5 predict platinum-based concurrent chemoradiotherapy response in nasopharyngeal carcinoma patients

• DOI: 10.18632/oncotarget.19725
• Publication Date: 2017-07-31T12:50:09Z
• Authors: Zhen Guo; Youhong Wang; Yu Zhao; Yi Jin; Liang An; Bin Wu; Zhaoqian Liu; Xiaoping Chen; Honghao Zhou; Hui Wang; Wei Zhang
• Keywords: Chemoradiotherapy

LncRNA GAS5 plays a tumor suppressive role in variety of human cancers and promises to be novel diagnostic biomarker, therapy target, as well prognostic biomarker. However, the nasopharyngeal carcinoma (NPC) remains elusive. The objective present study was evaluate effect single nucleotide polymorphisms (SNPs) on treatment efficacy toxicity NPC patients receiving chemoradiotherapy. Three potentially functional SNPs were genotyped 267 validated another 238 treated with chemoradiotherapy from southern China. Multivariate logistic regression analyses stratification used estimate association candidate toxic reactions. Our results showed that rs2067079 kept consistent severe myelosuppression neutropenia discovery set (OR=2.403, P=0.009; OR=2.454, P=0.015; respectively), validation (OR=3.653, P=0.027; OR=4.767, P=0.016; combined dataset (OR=1.880, P=0.007; OR=2.079, P=0.005; respectively). CT genotype carriers presented an even more remarkable increased risk (OR=3.878, P=0.003) (OR=3.794, P=0.009) subgroups taking paclitaxel+platinum concurrent regimen. Besides, we found gene-does rs6790, incidence rate decreased 23.56% 17.21% 10% 30.4% 20.9% 17.1% for rs6790 GG vs GA AA carriers. indicate potential lncRNA predictive biomarkers induced reactions patients.